See more : Urstadt Biddle Properties Inc. (UBP-PH) Income Statement Analysis – Financial Results
Complete financial analysis of Evotec SE (EVO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evotec SE, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Joshua Gold Resources Inc. (JSHG) Income Statement Analysis – Financial Results
- Equippp Social Impact Technologies Limited (EQUIPPP.NS) Income Statement Analysis – Financial Results
- Inergy Technology Inc. (6693.TWO) Income Statement Analysis – Financial Results
- The Investment Company plc (INV.L) Income Statement Analysis – Financial Results
- Corazon Mining Ltd (CRZNF) Income Statement Analysis – Financial Results
Evotec SE (EVO)
About Evotec SE
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 781.43M | 751.45M | 618.03M | 500.92M | 446.44M | 375.41M | 257.63M | 164.51M | 127.68M | 89.50M | 85.94M | 87.27M | 80.13M | 55.26M | 42.68M | 39.61M | 32.89M | 67.35M | 64.12M | 1.94M | 3.57M | 0.00 | 0.00 |
| Cost of Revenue | 606.38M | 577.38M | 466.49M | 375.18M | 313.55M | 263.39M | 175.06M | 105.95M | 89.69M | 60.12M | 54.72M | 56.24M | 45.14M | 30.92M | 24.26M | 21.98M | 24.86M | 44.40M | 42.99M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 175.05M | 174.07M | 151.54M | 125.74M | 132.89M | 112.02M | 82.57M | 58.55M | 37.99M | 29.38M | 31.22M | 31.02M | 34.99M | 24.35M | 18.42M | 17.64M | 8.02M | 22.95M | 21.13M | 1.94M | 3.57M | 0.00 | 0.00 |
| Gross Profit Ratio | 22.40% | 23.16% | 24.52% | 25.10% | 29.77% | 29.84% | 32.05% | 35.59% | 29.75% | 32.83% | 36.33% | 35.55% | 43.66% | 44.06% | 43.16% | 44.52% | 24.40% | 34.08% | 32.95% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 57.52M | 76.64M | 72.20M | 63.95M | 58.43M | 35.62M | 17.61M | 18.11M | 18.34M | 12.40M | 9.66M | 8.34M | 8.44M | 6.12M | 20.95M | 42.54M | 36.94M | 30.31M | 9.30M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 152.74M | 142.70M | 96.02M | 77.24M | 66.55M | 57.01M | 42.38M | 27.01M | 25.17M | 17.99M | 16.60M | 16.30M | 15.76M | 15.96M | 16.70M | 19.95M | 17.81M | 18.58M | 15.54M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 16.87M | 13.49M | 9.42M | 9.50M | 9.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 169.61M | 156.19M | 105.45M | 77.24M | 66.55M | 57.01M | 42.38M | 27.01M | 25.17M | 17.99M | 16.60M | 16.30M | 15.76M | 15.96M | 16.70M | 19.95M | 17.81M | 18.58M | 15.54M | 6.10M | 5.27M | 5.02M | 4.27M |
| Other Expenses | -4.57M | -79.62M | -67.78M | -67.21M | -66.60M | 257.00K | -209.00K | 4.00K | 263.00K | 39.00K | 16.00K | 171.00K | 1.49M | 1.80M | -3.29M | -11.87M | 149.00K | 274.00K | 614.00K | -38.30M | -41.99M | -28.93M | -17.01M |
| Operating Expenses | 222.56M | 153.22M | 109.86M | 73.98M | 58.38M | 49.22M | 43.89M | 21.81M | 40.52M | 27.24M | 27.05M | 30.72M | 30.65M | 27.17M | 38.03M | 63.13M | 57.24M | 53.75M | 36.26M | -32.20M | -36.72M | -23.91M | -12.74M |
| Cost & Expenses | 828.93M | 730.60M | 576.36M | 449.16M | 371.92M | 312.61M | 218.96M | 127.76M | 130.21M | 87.35M | 81.77M | 86.96M | 75.79M | 58.08M | 62.30M | 85.11M | 82.10M | 98.15M | 79.25M | -32.20M | -36.72M | -23.91M | -12.74M |
| Interest Income | 9.26M | 8.34M | 2.27M | 1.34M | 2.23M | 898.00K | 903.00K | 863.00K | 533.00K | 469.00K | 261.00K | 655.00K | 413.00K | 241.00K | 499.00K | 2.96M | 1.96M | 1.37M | 851.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 11.74M | 13.15M | 9.25M | 8.47M | 7.46M | 2.59M | 1.26M | 1.52M | 1.73M | 1.62M | 1.87M | 1.86M | 1.86M | 866.00K | 433.00K | 839.00K | 483.00K | 671.00K | 698.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 92.98M | 81.66M | 67.61M | 56.06M | 48.81M | 31.29M | 20.77M | 11.89M | 11.94M | 8.54M | 9.17M | 8.82M | 6.61M | 5.51M | 4.78M | 5.13M | 8.94M | 9.61M | 16.40M | 2.14M | 2.03M | 0.00 | 0.00 |
| EBITDA | 24.13M | -86.08M | 298.41M | 75.50M | 86.77M | 105.88M | 35.50M | 45.57M | 24.93M | 5.00M | -14.07M | 4.51M | 13.90M | 9.49M | -39.61M | -70.01M | -36.08M | -22.15M | -18.44M | -67.56M | -31.12M | -23.91M | -12.74M |
| EBITDA Ratio | 3.09% | 12.53% | 15.36% | 19.76% | 27.25% | 25.25% | 22.65% | 29.87% | 7.99% | 12.50% | 15.84% | 11.40% | 17.82% | 16.76% | -40.03% | -125.03% | -109.71% | -29.29% | -0.94% | -1,452.23% | -870.96% | 0.00% | 0.00% |
| Operating Income | -47.51M | 12.50M | 27.32M | 48.52M | 62.59M | 77.46M | 37.50M | 31.34M | 11.64M | -6.38M | -21.35M | -3.20M | 5.21M | 1.72M | -42.30M | -73.21M | -58.12M | -36.76M | -32.97M | -30.26M | -33.15M | -23.91M | -12.74M |
| Operating Income Ratio | -6.08% | 1.66% | 4.42% | 9.69% | 14.02% | 20.63% | 14.55% | 19.05% | 9.12% | -7.13% | -24.84% | -3.67% | 6.50% | 3.10% | -99.10% | -184.81% | -176.72% | -54.58% | -51.42% | -1,562.82% | -927.80% | 0.00% | 0.00% |
| Total Other Income/Expenses | -33.09M | -174.81M | 195.98M | -22.72M | -6.03M | -5.46M | -11.16M | 1.61M | 851.00K | 1.22M | -2.30M | -6.55M | 49.00K | 2.15M | -21.16M | -28.20M | 1.37M | -1.46M | -20.40M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -80.59M | -153.96M | 236.98M | 25.81M | 56.56M | 72.00M | 26.33M | 32.95M | 12.49M | -5.16M | -23.65M | -5.01M | 5.26M | 3.87M | -44.82M | -75.97M | -54.41M | -35.98M | -35.53M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -10.31% | -20.49% | 38.34% | 5.15% | 12.67% | 19.18% | 10.22% | 20.03% | 9.78% | -5.76% | -27.52% | -5.75% | 6.56% | 7.00% | -105.00% | -191.78% | -165.44% | -53.41% | -55.42% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.32M | 21.70M | 21.47M | 19.56M | 19.33M | -12.06M | 2.33M | 6.11M | -4.03M | 1.82M | 1.79M | -7.49M | -1.40M | 882.00K | 678.00K | 2.32M | -6.35M | 320.00K | -4.53M | -798.91K | 96.08K | 23.90M | 12.77M |
| Net Income | -83.91M | -175.66M | 215.51M | 6.28M | 38.16M | 84.17M | 24.26M | 27.53M | 16.52M | -6.98M | -25.43M | 2.48M | 6.75M | 3.26M | -45.50M | -78.29M | -11.16M | -32.47M | -33.58M | -29.46M | -33.25M | -23.90M | -12.77M |
| Net Income Ratio | -10.74% | -23.38% | 34.87% | 1.25% | 8.55% | 22.42% | 9.42% | 16.73% | 12.94% | -7.80% | -29.59% | 2.84% | 8.42% | 5.90% | -106.59% | -197.63% | -33.92% | -48.21% | -52.38% | -1,521.56% | -930.49% | 0.00% | 0.00% |
| EPS | -0.47 | -0.99 | 1.30 | 0.04 | 0.25 | 0.57 | 0.16 | 0.20 | 0.13 | -0.05 | -0.21 | 0.02 | 0.06 | 0.03 | -0.43 | -0.82 | -0.16 | -0.49 | -0.65 | -1.36 | -37.01 | -39.97 | -40.78 |
| EPS Diluted | -0.47 | -0.99 | 1.30 | 0.04 | 0.25 | 0.57 | 0.16 | 0.20 | 0.12 | -0.05 | -0.21 | 0.02 | 0.06 | 0.03 | -0.43 | -0.82 | -0.16 | -0.49 | -0.65 | -1.36 | -37.01 | -39.97 | -40.78 |
| Weighted Avg Shares Out | 176.92M | 176.67M | 166.41M | 153.75M | 149.73M | 147.48M | 145.01M | 132.51M | 131.68M | 131.29M | 121.22M | 117.30M | 116.02M | 109.01M | 106.85M | 95.20M | 71.83M | 66.36M | 51.99M | 21.71M | 898.27K | 597.93K | 313.09K |
| Weighted Avg Shares Out (Dil) | 176.92M | 176.70M | 166.41M | 153.75M | 149.73M | 147.48M | 145.01M | 132.51M | 137.63M | 131.29M | 121.22M | 117.30M | 116.02M | 109.01M | 106.85M | 95.20M | 71.83M | 66.36M | 51.99M | 21.71M | 898.27K | 597.93K | 313.09K |
Evotec Announces CEO Transition
HAMBURG, GERMANY / ACCESSWIRE / January 3, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that CEO Dr Werner Lanthaler has informed the company, that he has decided to...
Evotec receives US$ 2.5 M Grant to Leverage Human iPSC-Derived Teratogenicity Platform for Global Health Programmes
EVOTEC JOINS THE BILL & MELINDA GATES FOUNDATION FUNDED GLOBAL HEALTH DISCOVERY COLLABORATORY ("GHDC") AS A NEW ADDITION TO THE FIFTEEN COLLABORATORY PLATFORMS GRANT FROM THE BILL & MELINDA GATES FOUNDATION PROVIDES GHDC MEMBER INSTITUTIONS WITH ACCESS TO EVOTEC'S IPSC-DERIVED...
Evotec Enters Partnership with Charité to Expand Molecular Patient Database in Autoimmune Diseases
GENERATION OF LONGITUDINAL PANOMICS DATA TO IMPROVE THE DISEASE UNDERSTANDING OF ANCA-ASSOCIATED VASCULITIS CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN WILL COLLECT BIOSAMPLES FROM ANCA-ASSOCIATED VASCULITIS PATIENTS EVOTEC WILL LEVERAGE ITS UNIQUE PANOMICS TECHNOLOGIES TO IMPROVE PATIENT STRATIFICATION AND CREATE NEW ENTRY POINTS...
Evotec-partner Jingxin Receives Approval for EVT201 in China
EVT201 APPROVED BY THE CHINESE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ("NMPA") AS A NOVEL SHORT-TERM TREATMENT OF INSOMNIA EVOTEC'S LICENCE PARTNER ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD ("JINGXIN") WILL LEAD ALL COMMERCIALISATION EFFORTS FOR EVT201 IN CHINA AND SOUTH KOREA HAMBURG, GERMANY...
Evotec Presents Precision Medicine Platforms for Accelerated Pipeline Building at Capital Markets Day
PRECISION MEDICINE CAPABILITIES SHAPING (NEW) MARKETS WITH FIRST-IN-CLASS THERAPEUTICS PANOMICS, IPSC & A.I./M.L. PLATFORMS ARE THE STEP CHANGE FOR GROWTH AND ACCELERATED PIPELINE BUILDING CONFIRMATION OF ACTION PLAN 2025 GOALS AND PROGRESS UPDATE HAMBURG, GERMANY / ACCESSWIRE / November 15,...
Evotec: Attractive Spec 'Buy', But Merck KGaA Is Still Better
Evotec SE's appeal is based on its valuation and upside potential in the drug discovery and development sector. The company's financial performance is average, with negative margins and subpar business model specifics for 2022. Despite some issues, EVO remains a...
Evotec SE (EVO) Q3 2023 Earnings Call Transcript
Evotec SE (NASDAQ:EVO ) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Werner Lanthaler - Chief Executive Officer Laetitia Rouxel - Chief Financial Officer Cord Dohrmann - Chief Scientific Officer Craig Johnstone - Chief Operating...
Evotec SE Reports Results for the First Nine Months 2023 and Provides Corporate Update
CONTINUATION OF STRONG GROWTH IN DEMANDING MARKETS PARADIGM-SHIFTING OFFERINGS ARE STRONGEST GROWTH DRIVERS PIPELINE PROGRESS, E.G. WITH ADVANCED ASSET IN NEURODEGENERATION ALL ELEMENTS OF GUIDANCE CONFIRMED HAMBURG, GERMANY / ACCESSWIRE / November 8, 2023 / Evotec SE (Frankfurt Stock Exchange:...
Evotec and Dewpoint Therapeutics Enter Strategic Partnership in Oncology
STRATEGIC PARTNERSHIP TO ACCELERATE DEWPOINT'S LEADING ONCOLOGY PIPELINE PROGRAMMES TO INVESTIGATIONAL NEW DRUG APPLICATIONS COLLABORATION LEVERAGES EVOTEC'S FULLY INTEGRATED, CLINICAL-ENABLING INDIGO CAPABILITY PLATFORM AGREEMENT IS BASED ON A RISK-SHARING ARRANGEMENT FOLLOWED BY MILESTONE AND ROYALTY PAYMENTS TO EVOTEC BASED ON...
Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Accelerate Oncology Pipeline
HAMBURG, Germany and BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Dewpoint Therapeutics today announced a strategic R&D collaboration to advance Dewpoint's leading oncology pipeline programs of condensate modifying...
Source: https://incomestatements.info
Category: Stock Reports